COMP <GO>
SWBI vs TMO // ENTERPRISE SCALE & MARKET CAP
Smith & Wesson Brands Inc. (NASDAQ) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: SWBI 5
— TMO 6
▲ ENTERPRISE SCALE & MARKET CAP LEADER: TMO
LAST: $13.66 (-1.66%) • MKT CAP: $735.4M
market-cap
$735.4M
LAST: $709.18 (+0.71%) • MKT CAP: $262.22B
market-cap
$262.22B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SWBI VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SWBI | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 26.90% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 6.70% | 9.30% | -2.60 | TMO | /roic <GO> |
| EV/EBITDA & P/E Valuation | 14.5x | 30.4x | -15.90 | SWBI | /valuation <GO> |
| Free Cash Flow Yield | 12.30% | 2.40% | +9.90 | SWBI | /fcf-yield <GO> |
| Operating Margin | 5.60% | 17.40% | -11.80 | TMO | /operating-margins <GO> |
| Net Profit Margin | 3.50% | 15.10% | -11.60 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 10.40% | 3.90% | +6.50 | SWBI | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 3.16% | 0.24% | +2.92 | SWBI | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.08 | 4.50 | +0.58 | SWBI | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.6 | 62.9 | -18.30 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.94 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 37.0x | 36.3x | +0.70 | TMO | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $735.4M | $262.22B | -$261.48B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SWBI REV | TMO REV | SWBI GROSS % | TMO GROSS % | SWBI FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $523.8M | $44.56B | 26.9% | — | $90.4M | $6.29B |
| FY 2024 | $474.7M | $42.88B | 26.8% | — | -$28.8M | $7.27B |
| FY 2023 | $535.8M | $42.86B | — | — | $106.7M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SWBI // BETA —
TMO // BETA 0.94